KRAS G12C
Clinical trials for KRAS G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C trials appear
Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine combo tackles Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a custom-made vaccine that uses a patient's own immune cells to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given together with two immunotherapy drugs (anti-PD-1 and anti-CTLA4) to boost the immune system's attack on adv…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated May 26, 2026 05:00 UTC
-
New hope for hard-to-treat cancers: experimental drug enters human testing
Disease control OngoingThis early-stage study tests a new drug called TT125-802 in about 50 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also watch for any tumor shrinkage an…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New immunotherapy targets tough pancreatic cancers
Disease control OngoingThis study tests a new immunotherapy called ELI-002 7P for people with pancreatic or other solid tumors that have certain gene mutations (KRAS/NRAS). The treatment aims to help the immune system fight cancer cells after standard treatments like surgery and chemotherapy. About 158…
Matched conditions: KRAS G12C
Phase: PHASE1, PHASE2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:54 UTC